MedTrace Logo

ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy

NCT02145416 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2018-06-06

No results posted yet for this study

Summary

This is a single arm, single centre imaging study which will be offered to all consecutive, eligible patients receiving radical chemoradiation therapy (CRT) for anal cancer within Oxford University Hospitals.

Investigations

* Dynamic contrast enhanced magnetic resonance imaging (DCE MRI)
* Diffusion weighted magnetic resonance imaging (DWI MRI)
* MRI scan designed to measure the T1 or produce T1-weighed images (T1 MRI)
* MRI scan designed to measure the T2\* or produce T2\*-weighed images (T2\* MRI)
* Perfusion computed tomography (pCT)
* Fludeoxyglucose positron emission tomography (FDG PET/CT)

Study Design: Observational

Target Population: Patients undergoing radical CRT for anal cancer in Oxford University Hospitals National Health Service (NHS) Trust.

Duration on study: Patients should be on study for a maximum of 5 months.

Patient care post-trial: Follow up as per local standard.

No. of Study Site(s): Single Centre, United Kingdon (UK)

End of study: Last Patient, last assessment of response. Patients should be on study for a maximum of 5 months.

Conditions

Sponsors & Collaborators

  • Oxford University Hospitals NHS Trust

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Rebecca Muirhead, MBCHB, MRCP, FRCR, MD · Oxford University Hospitals NHS Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-27
Primary Completion
2017-12-08
Completion
2018-04-12

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02145416 on ClinicalTrials.gov